GlobeNewswire: Andromeda Biotech Ltd. Contains the last 10 of 9 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T19:37:18ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2014/02/24/612510/10069592/en/Andromeda-Acquires-DiaPep277-Rights-From-Teva.html?f=22&fvtc=4&fvtv=11278Andromeda Acquires DiaPep277 Rights From Teva2014-02-24T09:13:49Z<![CDATA[YAVNE, Israel, Feb. 24, 2014 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. announces that it entered into an agreement with Teva Pharmaceutical Industries Ltd. for the acquisition of Teva's rights for Andromeda's drug, DiaPep277]]>https://www.globenewswire.com/news-release/2014/01/12/601796/10063891/en/Andromeda-Announces-the-Acceptance-of-Two-Manuscripts-for-Publication-Describing-Its-Phase-3-DIA-AID-1-Study.html?f=22&fvtc=4&fvtv=11278Andromeda Announces the Acceptance of Two Manuscripts for Publication Describing Its Phase 3 DIA-AID 1 Study2014-01-12T14:12:43Z<![CDATA[YAVNE, Israel, Jan. 12, 2014 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. announces that two peer-reviewed articles were accepted for publication in Diabetes Care. The publications, which discuss clinical results from the phase 3 DIA-AID 1 study, will appear in the March issue accompanied by an Editorial.]]>https://www.globenewswire.com/news-release/2013/12/18/597821/10061908/en/Andromeda-Announces-First-Patient-Dosed-in-Extension-Study-to-Its-Phase-3-Clinical-Trial-DIA-AID-2-in-Patients-With-Type-1-Diabetes.html?f=22&fvtc=4&fvtv=11278Andromeda Announces First Patient Dosed in Extension Study to Its Phase 3 Clinical Trial DIA-AID 2 in Patients With Type 1 Diabetes2013-12-18T13:32:32Z<![CDATA[YAVNE, Israel, Dec. 18, 2013 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. today announces that the first patient was dosed with DiaPep277]]>https://www.globenewswire.com/news-release/2013/06/05/552188/10035325/en/Andromeda-Announces-the-Results-of-an-Extension-to-Its-Phase-III-Study.html?f=22&fvtc=4&fvtv=11278Andromeda Announces the Results of an Extension to Its Phase III Study2013-06-05T11:19:40Z<![CDATA[YAVNE, Israel, June 5, 2013 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. announces the results from an Extension Study to its Phase III Clinical trial in type 1 diabetes patients treated with DiaPep277]]>https://www.globenewswire.com/news-release/2012/09/12/490283/10004892/en/Andromeda-Biotech-Successfully-Completes-Patient-Recruitment-in-Phase-III-Confirmatory-Trial-for-Its-Lead-Drug-DiaPep277-for-Type-1-Diabetes.html?f=22&fvtc=4&fvtv=11278Andromeda Biotech Successfully Completes Patient Recruitment in Phase III Confirmatory Trial for Its Lead Drug, "DiaPep277" for Type 1 Diabetes2012-09-12T07:34:24Z<![CDATA[YAVNE, Israel, Sept. 12, 2012 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. (]]>https://www.globenewswire.com/news-release/2012/05/28/477854/257372/en/Andromeda-Announces-FDA-Orphan-Drug-Designation-for-DiaPep277-for-the-Treatment-of-Type-1-Diabetes-With-Residual-Beta-Cell-Function.html?f=22&fvtc=4&fvtv=11278Andromeda Announces FDA Orphan Drug Designation for DiaPep277 for the Treatment of Type 1 Diabetes With Residual Beta Cell Function2012-05-28T10:45:00Z<![CDATA[YAVNE, Israel, May 28, 2012 (GLOBE NEWSWIRE) -- ]]>https://www.globenewswire.com/news-release/2012/05/09/476180/255447/en/Andromeda-Announces-That-Further-Data-Analyses-Support-Primary-Endpoint-in-Andromeda-Biotech-s-Phase-III-Clinical-Study.html?f=22&fvtc=4&fvtv=11278Andromeda Announces That Further Data Analyses Support Primary Endpoint in Andromeda Biotech's Phase III Clinical Study2012-05-09T16:21:15Z<![CDATA[YAVNE, Israel, May 9, 2012 (GLOBE NEWSWIRE) -- ]]>https://www.globenewswire.com/news-release/2011/11/22/462261/239054/en/Andromeda-Announces-Phase-III-Clinical-Study-With-DiaPep277-R-a-Novel-Immunotherapeutic-Agent-for-Type-1-Diabetes-Met-Primary-Endpoint.html?f=22&fvtc=4&fvtv=11278Andromeda Announces Phase III Clinical Study With DiaPep277(R), a Novel Immunotherapeutic Agent for Type 1 Diabetes, Met Primary Endpoint2011-11-22T15:38:27Z<![CDATA[
DiaPep277]]>https://www.globenewswire.com/news-release/2010/06/17/423403/194544/en/Teva-Exercises-Option-to-Invest-in-Andromeda-Biotech.html?f=22&fvtc=4&fvtv=11278Teva Exercises Option to Invest in Andromeda Biotech2010-06-17T11:41:35Z<![CDATA[Teva and CBI Investment Used for Conducting DIA-AID 2, a Confirmatory Phase III Study in Type 1 Diabetes Adult Patients YAVNE, Israel, June 17, 2010 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. announces that Teva Pharmaceutical Industries Ltd. decided to exercise its option to invest in Andromeda Biotech Ltd. ("Andromeda") at a company per-money valuation of 170 million US dollars.]]>